Person: DANE, FAYSAL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
DANE
First Name
FAYSAL
Name
9 results
Search Results
Now showing 1 - 9 of 9
Publication Metadata only Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: Relationship with pathological factors and prognostic impact on survival(KARGER, 2007) ÇELİKEL, ÇİĞDEM; Cabuk, Devrim; Basaran, Gul; Celikel, Cigdem; Dane, Faysal; Yumuk, P. Fulden; Iyikesici, M. Salih; Ekenel, Meltem; Turhal, N. SerdarBackground: Angiogenesis is one of the key steps in solid tumor growth and metastasis. We planned to investigate the prognostic significance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1 alpha (HIF-1 alpha) and CD34 expressions as markers of angiogenesis in gastric cancer. Patients and Methods: We retrospectively reviewed the medical records of 51 gastric cancer patients who had total or subtotal gastrectomy at Marmara University Hospital from 1990 to 2004 and evaluated the expression of VEGF, HIF-1 alpha and CD34 by immunohistochemistry in their archival tumor tissues. We recorded the clinical and pathological characteristics of these patients and analyzed their survival outcome. Results: Thirty out of 51 patients were males. The median age was 63 years (range 34-81). The median follow-up was 17 months. Thirty-six patients had node-positive disease. The majority of patients (n = 43) had T2 and T3 disease. Vascular and lymphatic invasions were present in 57 and 77% of tumors, respectively. VEGF and HIF-1 alpha were positive in 65 and 71% of tumors. The median CD34 staining score was 19 (3-68). VEGF, HIF-1 alpha and CD34 expressions were more frequent in tumors without serosal invasion (p = 0.01, p = 0.01 and p = 0.003, respectively). CD34 expression was significantly more frequent in tumors with VEGF and HIF-1 alpha expression (p = 0.00, p = 0.00). HIF-1 alpha expression was more frequent in tumors with VEGF expression (p = 0.00). The 5year overall survival was 45%. VEGF, HIF-1 alpha, CD34 expressions and other pathological characteristics were found to have no impact on survival. Conclusion: VEGF, HIF-1 alpha and CD34 expressions were more common in tumors without serosal invasion. As a future perspective, biological agents targeting VEGF and HIF-1 alpha might be more effective at earlier stages of gastric cancer. Copyright (c) 2007 S. Karger AG, Basel.Publication Metadata only Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer(WILEY, 2009) DANE, FAYSAL; Kefeli, U.; Dane, F.; Yumuk, P. F.; Karamanoglu, A.; Iyikesici, S.; Basaran, G.; Turhal, N. S.The long-term use of subcutaneous implanted ports for chemotherapy in cancer patients has been associated with the occurrence of thrombosis and infection. In this study, we compared the safety and efficacy of administration of 1000 U of heparin flushes in prolonged interval (every 6 weeks) with standard dose and schedule (500 U every 4 weeks) for port-related infections and thrombosis during periods of non-use. Data were collected retrospectively from patients treated for various cancer types (matched as 2: 1 for age, gender, stage of the disease). Patients who had diseases that could cause thrombosis or bleeding in their past medical history, or were taking oral anticoagulants, or had contraindications for heparin usage were excluded. After completing their chemotherapy, 59 patients received prolonged interval, while 30 patients received standard schedule. All patients were followed for at least 1 year. No clinically documented port-related infection or thrombosis has been found in both groups. Also, none of the devices was removed during this time. Prophylactic flushing of central venous ports with 1000 U of heparin in every 6 weeks might be a safe, easy, cheaper, comfortable and effective alternative to standard dose and schedule for preventing thrombosis and infections.Publication Metadata only Rektum kanseri̇ni̇n adjuvan tedavi̇si̇nde radyoterapi̇yle eş zamanli tegafur urasi̇l uft foli̇ni̇k asi̇t fa uygulamasi tolerabi̇li̇te değerlendi̇rmesi̇(2006-04-19) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; YUMUK, PERRAN FULDEN; ATASOY B. M. , ABACIOĞLU U., ÖZGEN Z., DANE F., YUMUK P. F. , MAYADAĞLI A., TURHAL S., ŞENGÖZ K. M.Publication Metadata only Causes and risk factors for liver injury following bone marrow transplantation(LIPPINCOTT WILLIAMS & WILKINS, 2003) DANE, FAYSAL; Ozdogan, O; Ratip, S; Al Ahdab, Y; Dane, F; Al Ahdab, H; Imeryuz, N; Tozun, NGoals: A retrospective study of pretransplantation risk factors predisposing to liver injury following bone marrow transplantation (BMT). Background: Liver complications are a major cause of morbidity and mortality following BMT. Determination of the pretransplantation factors that are likely to lead to liver injury may allow earlier diagnosis after BMT and may possibly improve prognosis. Study: Medical records of BMT patients were reviewed, and results of serial liver function tests and HBV/HCV serology during the pre- and posttransplantation 1-year period were noted. Presence of liver injury was defined as alanine aminotransferase levels twice the upper limit of normal. Forty-four allogeneic and 17 autologous BMTs, performed between 1990 and 2000, were analyzed in the study. Results and Conclusion: One-year survival was 77% (34 of 44 patients) for allogeneic BMT and 52% (9 of 17 patients) for autologous BMT. Seventy-two percent (32 of 44) of allogeneic transplant recipients and 47% (8 of 17) of autologous transplant recipients had liver injury during the first year of BMT. The most frequent causes of liver injury were graft-versus-host disease and drug hepatotoxicity for allogeneic BMT and drug hepatotoxicity for autologous BMT. Fulminant hepatic failure occurred in one allogeneic transplant recipient who was a pretransplantation HBV carrier and led to death. Multivariate regression analysis showed that pretransplantation HBV/HCV positivity and pretransplantation elevated liver enzyme levels of any cause were predictive risk factors for post-BMT liver injury, and close follow-up, early diagnosis, and treatment are highly recommended for BMT patients with these risk factors.Publication Metadata only Markers of bone turnover in patients with lung cancer(2008) DANE, FAYSAL; Dane, Faysal; Turk, H. Mehmet; Sevinc, Alper; Buyukberber, Suleyman; Camci, Celalettin; Tarakcioglu, MehmetINTRODUCTION: Bone metastases may change the primary treatment modality, especially if the bone is the only site of metastasis in patients considered to be in the early stage of lung cancer. It is usually diagnosed by imaging techniques. However, the diagnostic yields of imaging methods are limited. Some bone markers such as propeptides of type-1 collagen, pyridinoline cross-links and deoxypyridinoline (D-PYD) cross-links, serum osteocalcin, alkaline phosphatase are thought to be useful in the detection of bone metastasis in lung cancer. Thus, we aimed to determine the clinical usefulness of bone turnover markers in the assessment of bone metastases in patients with lung cancer. MATERIAL AND METHODS: Urinary D-PYD, calcium, and serum osteocalcin, calcium and total alkaline phosphatase (T-ALP) were measured in 60 lung cancer patients. Patients were evaluated by technetium 99 (99Tc) bone scintigraphy. The comparisons of measured values in patients with and without bone metastasis were done by using appropriate statistical methods. RESULTS: Fifty-four males and six females were included into study. Twenty-two patients had bone metastases, while 38 did not. Forty-two patients were nonsmall-cell lung cancer, whereas 18 were small-cell carcinoma. Urinary D-PYD level was the unique value that was statistically significantly higher in patients with bone metastases than that level in patients without bone metastasis (p < 0.05). CONCLUSION: Our study suggests that urinary measurement of D-PYD might be helpful in detecting bone metastasis in lung cancer. The high urinary D-PYD level may be an early sign of occult metastases in patients with no bone metastasis assessed by scintigraphic techniques.Publication Metadata only Benefit from adjuvant anthracyclines according to hormone receptor status(AMER SOC CLINICAL ONCOLOGY, 2008) DANE, FAYSAL; Basaran, G. Atalay; Cabuk, D.; Teomete, M.; Gulluoglu, B.; Kaya, H.; Dane, F.; Yumuk, P. F.; Turhal, N. S.Publication Metadata only Does the incidence of anal canal cancers differ in Moslem societies?(SPRINGER, 2005) DANE, FAYSAL; Yumuk, PF; Abacioglu, U; Demir, G; Cabuk, D; Dane, F; Gumus, M; Ozguroglu, M; Ekenel, M; Basaran, G; Turhal, NSPublication Open Access Interstitial pneumonitis associated with docetaxel administration(OXFORD UNIV PRESS, 2006-09) CEYHAN, BERRİN; Dane, Faysal; Topaloglu, Nurhayat; Abul, Yasin; Yumuk, Perran F.; Turhal, Nazim S.; Ceyhan, Berrin; Celikel, Turgay; Caglar, Hale; Basaran, Gul; Ahiskali, RenginPublication Metadata only The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients(SPRINGER, 2004) DANE, FAYSAL; Yumuk, PF; Aydin, SZ; Dane, F; Gumus, M; Ekenel, M; Aliustaoglu, M; Karamanoglu, A; Sengoz, M; Turhal, SN